Cerus Corporation, a biomedical products company focused in the field of blood transfusion safety, and its distribution partner CEI Group (Brazil) announced a donation of INTERCEPT Blood System ...
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has entered into an agreement with Haemonetics Corporation (NYSE:HAE) for the sale of Haemonetics’ Acrodose ...
Blood borne pathogens pose a great risk to the health of employees if contact is made with another’s blood/bodily fluids. In general, if contact with another person’s blood or bodily fluids is ...
Firm is pushing on with U.S. commercialization of CE-marked Intercept plasma and platelet system. Cerus hopes to raise about $21 million through a public offering of common stock and warrants, priced ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of ...
Identification of new pathogens requires a rapid response from industry to develop new tests and the FDA to assess test safety and efficacy. A report evaluates the new OpenArray system that offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results